RNSTRENASANT CORPMid cap · $3.92B · FY ending 2025-12-31
$42.52+0.76% · 2026-07-10 · EOD
45/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality—
margins & F-ScoreValue51
P/E 20.5 · 89% of 12-mo rangeMomentum63
golden · price above 200-daySmart Money21
selling · 0 funds · 0P/3S insidersBullish stackGolden crossAbove 200-day
vs S&P 500+10.2%
6-mo excess Trailing performance1M +2.4%
3M +7.0%
6M +19.7%
YTD +20.2%
1Y +11.3%
P/E vs its last 12 months (our price history): 16.1 low → 21.1 high
Current price sits at the 89th percentile of that window — near the top (richer). We only compare against the price history we own (no paid multi-year multiples — nothing invented).
ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of 20%. Annual figures from SEC XBRL.
Dividend & capital return
Payout ratio43.4%
comfortable Shareholder yield2.3%
dividends + buybacks Annual figures from SEC cash-flow statements. Shareholder yield = total cash returned ÷ market cap.
Net selling0P / 3S insiders · 0 funds hold · 0 Congress buys
Recent insidersEngel Connie L · DirectorSELL$51,410
DALE ALBERT J III · DirectorSELL$65,662
WAYCASTER C MITCHELL · Executive Vice ChairmanSELL$501,808
Bhealth · 77/100
Self-fundingSelf-funding — profitable · generates cash
- ●Active dilution shelf An effective S-3 shelf with 2 prospectus filing(s) in 12 months — shares may be getting sold into the market.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.